Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia

Between September 1986 and June 1997, 24 children with high-risk ALL in CR1 were allografted after TAM (fractionated TBI, high-dose Ara-C, and melphalan; n = 10) or BAM protocol (busulfan, high-dose Ara-C, and melphalan; n = 14). The EFS for transplants from sibling donors was 33% with TAM and 62% w...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) Vol. 34; no. 8; pp. 667 - 673
Main Authors: DAI, Q. Y, SOUILLET, G, BERLIER, P, DAVID, M, BERTHIER, J. C, MASSENAVETTE, B, CONTAMIN, B, PHILIPPE, N, BERTRAND, Y, GALAMBRUN, C, BLEYZAC, N, MANEL, A. M, BRUNO, B, SOUILLET, A. L, HOMOLE, E, PAGES, M. P
Format: Journal Article
Language:English
Published: Basingstoke Nature Publishing Group 01-10-2004
Subjects:
ALL
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Between September 1986 and June 1997, 24 children with high-risk ALL in CR1 were allografted after TAM (fractionated TBI, high-dose Ara-C, and melphalan; n = 10) or BAM protocol (busulfan, high-dose Ara-C, and melphalan; n = 14). The EFS for transplants from sibling donors was 33% with TAM and 62% with BAM (P = 0.148). The probability of acute GvHD was 70% with TAM and 15% with BAM (P = 0.003). Four of 17 evaluable patients relapsed: one after TAM and three after BAM. In all, 46 other children transplanted in CR beyond CR1 were studied for sequelae. Long-term side effects were more frequent in TAM vs BAM. In children with ALL, busulfan may be a good alternative to TBI to improve the quality of life.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0268-3369
1476-5365
DOI:10.1038/sj.bmt.1704605